Image source: Kite Pharma, Inc.Following the release of interim results from a mid stage trial, Kite Pharma, Inc. (NASDAQ: KITE) appears on track to become the first company to launch a chimeric antigen receptor T-cell, or CAR-T, therapy. If so, then the impressive efficacy observed in this trial may revolutionize how doctors tackle tough-to-treat lymphomas.Continue reading
Comment on How Kite Pharma Could Change Cancer Treatment Forever
newsfeedback@fool.com (Todd Campbell), The Motley Fool
Tue, 09/27/2016 - 10:41am
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more